Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention.
Braddock
Martin
M
Disease Sciences Section, Discovery Bioscience Department, AstraZeneca R&D Charnwood, Bakewell Road, Loughborough, Leicestershire, LE11 5RH, UK. martin.braddock@astrazeneca.com
Quinn
Anthony
A
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D006801:Humans; D007249:Inflammation / Q000188:drug therapy* / Q000473:pathology; D007375:Interleukin-1 / Q000037:antagonists & inhibitors*; D017472:Receptors, Interleukin-1 / Q000378:metabolism; D015398:Signal Transduction
D000893:Anti-Inflammatory Agents; D007375:Interleukin-1; D017472:Receptors, Interleukin-1